普瑞巴林联合吗啡对癌性神经病理性疼痛的治疗效果探究  

Effect of pregabalin combined with morphine on cancer neuropathic pain

作　　者：何金莲 HE Jin-lian(Jiujiang First People’s Hospital,Jiujiang 332000,China)

机构地区：[1]九江市第一人民医院,332000

出　　处：《中国实用医药》2021年第35期145-147,共3页China Practical Medicine

摘　　要：目的探讨普瑞巴林联合吗啡对癌性神经病理性疼痛的治疗效果。方法60例癌性神经病理性疼痛患者,根据住院号单双号分为对照组和观察组,每组30例。对照组给予吗啡治疗,观察组给予吗啡联合普瑞巴林治疗。比较两组患者治疗前后活动状态下视觉模拟评分法(VAS)评分、静息状态下VAS评分、汉密尔顿抑郁量表(HAMD)评分、汉密尔顿焦虑量表(HAMA)评分、匹兹堡睡眠质量指数量表(PSQI)评分和生活质量量表(SF-36)评分、癌性神经病理性疼痛减轻时间、不良反应发生情况。结果治疗后,两组患者活动状态下VAS评分、静息状态下VAS评分、HAMD评分、HAMA评分、PSQI评分均较本组治疗前降低,SF-36评分较本组治疗前升高,且观察组患者活动状态下VAS评分(1.52±0.21)分、静息状态下VAS评分(1.51±0.21)分、HAMD评分(10.45±1.94)分、HAMA评分(10.25±1.56)分、PSQI评分(6.01±0.12)分显著低于对照组的(2.82±0.56)、(2.89±0.51)、(14.34±2.23)、(15.12±3.21)、(10.5±1.79)分,SF-36评分(92.21±4.30)分显著高于对照组的(80.55±4.12)分,差异具有统计学意义(P<0.05)。观察组患者癌性神经病理性疼痛减轻时间为(5.24±1.26)d,短于对照组的(7.66±2.57)d,差异具有统计学意义(P<0.05)。观察组患者不良反应发生率为3.33%,低于对照组的33.33%,差异具有统计学意义(P<0.05)。结论癌性神经病理性疼痛患者实施吗啡联合普瑞巴林治疗效果确切,可有效减轻疼痛,缓解焦虑、抑郁情绪,改善睡眠、生活质量,且有更高的安全性,值得临床推广和应用。Objective To discuss the therapeutic effect of pregabalin combined with morphine on cancer neuropathic pain.Methods A total of 60 patients with cancer neuropathic pain were divided into the control group and the observation group according to their hospitalization numbers,with 30 cases in each group.The control group was treated with morphine,and the observation group was treated with morphine in combination with pregabalin.Both groups were compared in terms of visual analogue scale(VAS)score at rest and during activity,Hamilton depression scale(HAMD)score,Hamilton anxiety scale(HAMA)score,Pittsburgh sleep quality index(PSQI)score and 36-item short-form health survey(SF-36)score,relief time of cancer neuropathic pain,and occurrence of adverse reactions.Results After treatment,the VAS score at rest and during activity,HAMD score,HAMA score,and PSQI score of the two groups were all lower than those of this group before treatment,and the SF-36 score was higher than that of this group before the treatment;the VAS score at rest(1.52±0.21)points,VAS score during activity(1.51±0.21)points,HAMD score(10.45±1.94)points,HAMA score(10.25±1.56)points,and PSQI score(6.01±0.12)points in the observation group of the observation group were significantly lower than(2.82±0.56),(2.89±0.51),(14.34±2.23),(15.12±3.21),(10.5±1.79)points of the control group,and the SF-36 score(92.21±4.30)points was significantly higher than(80.55±4.12)points of the control group;all the differences were statistically significant(P<0.05).The relief time of cancer neuropathic pain in the observation group was(5.24±1.26)d,which was shorter than(7.66±2.57)d in the control group,and the difference was statistically significant(P<0.05).The incidence of adverse reactions in the observation group was 3.33%,which was lower than 33.33%in the control group,and the difference was statistically significant(P<0.05).Conclusion Morphine in combination with pregabalin has definite effect on patients with cancer neuropathic pain,and it can effectively reli

关 键 词：普瑞巴林 吗啡 癌性神经病理性疼痛 治疗效果 

分 类 号：R730.5[医药卫生—肿瘤]